ATM Underexpression

CI-VAR-00004401Explore in graph →CIViC 179

Curated evidence

Evidence by cancer (6 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–6 of 6 evidence items across 5 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Lymphocytic Leukemia1
ATM Underexpression	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID1564 43 B-CLL patients with LoH or reduced protein levels (<50% normal expression, radioimmunoassay, western blot) of ATM were found to have significantly shorter overall survival (35.6 vs. 97.3 months; P=… (full text at CIViC) PMID 9788599 · Starostik et al., 1998 · Open in CIViC	civic
Gastric Adenocarcinoma1
ATM Underexpression	Olaparib	Predictive	D	Supports Sensitivity Response	4	accepted	EID878 Low ATM protein expression led to sensitivity to PARP inhibitors in TP53 -ve gastric cancer cell lines (8 lines were used for various aspects of this study). PMID 24841718 · Kubota et al., 2014 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Gastric Neoplasm2
ATM Underexpression	Olaparib + PaclitaxelCombination	Predictive	B	Supports Sensitivity Response	1	accepted	EID5215 A randomized phase 2 trial investigating the efficiency of Olaparib plus Paclitaxel vs. Placebo plus Paclitaxel in recurrent or metastatic gastric cancer patients. 123 patients received treatment. Com… (full text at CIViC) PMID 26282658 · Bang et al., 2015 · Open in CIViC	civic
ATM Underexpression	Olaparib + PaclitaxelCombination	Predictive	B	Does Not Support Sensitivity Response	4	submitted	EID7708 This double-blind, randomized, placebo-controlled, phase 3 study (GOLD) recruited Asian patients with advanced gastric cancer that had progressed after first-line chemotherapy. Patients were randomly … (full text at CIViC) PMID 29103871 · Bang et al., 2017 · Open in CIViC	civic

Malignant Neoplasm1
ATM Underexpression	KU-0060648 + NU7441Substitutes	Predictive	D	Supports Sensitivity Response	5	accepted	EID454 ATM-deficient H1395 and HT144 cancer cell lines showed growth inhibition when treated with DNA PKcs inhibitors KU-0060648 and NU7441. These agents also increased the lifespan of mice transfused with A… (full text at CIViC) PMID 23761041 · Riabinska et al., 2013 · Open in CIViC	civic

Malignant Pancreatic Neoplasm1
ATM Underexpression	(prognostic)	Prognostic	B	Supports Poor Outcome	2	accepted	EID1292 Absent expression of ATM, as assessed by IHC in 133 pancreatic ductal adenocarcinomas, was found to be associated with dismal prognosis (median survival, 9.6 months), whereas expression of ATM was ass… (full text at CIViC) PMID 25423555 · Kamphues et al., 2015 · Open in CIViC	civic